文献速递精神分裂症与精神病性障碍会诊联络精神医学

以色列精神分裂症患者COVID-19住院、死亡、疫苗接种及接种后趋势:纵向队列研究

COVID-19 hospitalisation, mortality, vaccination, and postvaccination trends among people with schizophrenia in Israel: a longitudinal cohort study.
PubMed 文献 · Lancet Psychiatry · 2021-08-06

完全接种后两组重症结局差异大幅缩小。

要点

  • 精神分裂症患者COVID-19住院和死亡风险显著高于对照人群。
  • 精神分裂症患者疫苗接种概率上升慢于对照,接种率偏低。
  • 完全接种后两组住院与死亡差异明显缩小,提示主动接种外展的重要性。

核心结论

  • 精神分裂症患者COVID-19住院和死亡风险更高,但疫苗接种率低于一般人群。
  • 针对精神分裂症患者主动外展的国家疫苗接种计划可大幅缩小COVID-19重症结局差异。

研究设计与样本

  • 使用以色列最大健康机构Clalit Health Services数据库,采用Cox比例风险回归模型和Kaplan-Meier分析评估纵向趋势。

临床怎么用

  • 对精神分裂症患者应主动外展推动COVID-19疫苗接种,以降低住院和死亡风险。
  • 应关注精神分裂症患者合并糖尿病、高血压、肥胖或缺血性心脏病等躯体共病对其接种行为的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Individuals with schizophrenia have an increased risk of severe COVID-19 outcomes, nonetheless, no previous study has provided a year-long account of this risk, or assessed postvaccination trends in this population. This study assessed temporal trends in COVID-19 hospitalisation and mortality among people with schizophrenia during the first year of the pandemic, the predictors for COVID-19 vaccination, postvaccination infection, admission to hospital, and mortality. METHODS: In this longitudinal cohort study, people with schizophrenia (n=25 539) and controls (n=25 539) were assessed for COVID-19 outcomes before and after vaccination, up to April 30, 2021. Cox proportional hazard regression models and Kaplan-Meier analyses were done to assess longitudinal trends. The study used the databases of Clalit Health Services, the largest health-care organisation in Israel. FINDINGS: The sample included 51 078 participants, of which 31 141 (61·0%) male and 19 937 (39·0%) female participants, with a mean age of 51·94 years (SD 15·62). Most of the sample was from the general Jewish population (75·9%), followed by the Arab (19·1%) and Jewish Ultraorthodox population (5·1%). Overall of 51 078 individuals, 356 (0·7%) people had been hospitalised, 133 (0·3%) had died, and a total of 27 400 (53·6%) had been vaccinated. People with schizophrenia showed a higher risk for COVID-19 hospitalisation (HR 4·81, 95% CI 3·57-6·48, p<0·0001) and mortality (HR 2·52, 95% CI 1·64-3·85, p<0·0001), and showed a sharper decline in survival as time progressed. The control group showed a sharper incline in probability to vaccinate (log-rank=309·88, p<0·0001). Medical comorbidity of diabetes, hypertension, obesity, or ischaemic heart disease played a significant role in predicting vaccination rates in the schizophrenia group (all p<0·0001), but not in the control group. Hospitalisation and mortality disparities remained higher among people with schizophrenia who had not been vaccinated in comparison to controls (incidence rate difference of 6·2 and 3·2, respectively) but substantially declined in fully vaccinated groups (incidence rate difference of 1·1 and -0·9, respectively). INTERPRETATION: People with schizophrenia have higher hospitalisation and mortality risk, yet have lower rates of vaccination than in the general population. Disparities in COVID-19 severe outcomes can be substantially reduced by national vaccination plans aimed at actively reaching out to people with schizophrenia. FUNDING: No funding.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Tzur Bitan D, Kridin K, Cohen AD, et al. COVID-19 hospitalisation, mortality, vaccination, and postvaccination trends among people with schizophrenia in Israel: a longitudinal cohort study. Lancet Psychiatry. 2021. PMID: 34364406. doi:10.1016/S2215-0366(21)00256-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。